Key result
Preoperative antiangiogenic therapy with bevacizumab and celecoxib was used in the management of a patient with alveolar soft-part sarcoma of the tongue.
Why the study?
Does the antiangiogenic combination of bevacizumab and celecoxib improve preoperative management in a patient with alveolar soft-part sarcoma of the tongue?
Case Report (n=1)
Does the antiangiogenic combination of bevacizumab and celecoxib improve preoperative management in a patient with alveolar soft-part sarcoma of the tongue?
This case report describes the potential role of antiangiogenic therapy (bevacizumab and celecoxib) in the preoperative management of highly vascularized alveolar soft-part sarcoma of the tongue.
May support preoperative antiangiogenic use in vascular tongue sarcomas; leaves open prospective validation.
Alveolar soft-part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue.
No takes yet. Share an insight, caveat, or question.
Conde et al. (2011) conducted a case report in Alveolar soft-part sarcoma (ASPS) of the tongue (n=1). Bevacizumab and celecoxib was evaluated. Preoperative antiangiogenic therapy with bevacizumab and celecoxib was used in the management of a patient with alveolar soft-part sarcoma of the tongue.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: